Complete financial analysis of Arcellx, Inc. (ACLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcellx, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Genus Paper & Boards Limited (GENUSPAPER.NS) Income Statement Analysis – Financial Results
- Kawanishi Warehouse Co.,Ltd. (9322.T) Income Statement Analysis – Financial Results
- Mobly S.A. (MBLY3.SA) Income Statement Analysis – Financial Results
- M LAKHAMSI INDUSTRIES LIMITED (MLINDLTD.BO) Income Statement Analysis – Financial Results
- Sterling Guaranty & Finance Limited (STRLGUA.BO) Income Statement Analysis – Financial Results
Arcellx, Inc. (ACLX)
About Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 110.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 2.22M | 1.04M | 629.00K | 326.00K | 0.00 |
| Gross Profit | 110.32M | -2.22M | -1.04M | -629.00K | -326.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 133.85M | 149.56M | 46.88M | 25.06M | 15.77M | 6.11M |
| General & Administrative | 66.35M | 41.70M | 18.14M | 7.04M | 2.21M | 2.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.35M | 41.70M | 18.14M | 7.04M | 2.21M | 2.20M |
| Other Expenses | 0.00 | 0.00 | 49.00K | 1.00K | 2.00K | 0.00 |
| Operating Expenses | 200.20M | 191.26M | 65.02M | 32.10M | 17.97M | 8.31M |
| Cost & Expenses | 200.20M | 191.26M | 65.02M | 32.10M | 17.97M | 8.31M |
| Interest Income | 23.70M | 4.30M | 300.00K | 1.00K | 0.00 | 0.00 |
| Interest Expense | 3.84M | 1.72M | 10.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.04M | 2.22M | 1.04M | 629.00K | 326.00K | 93.00K |
| EBITDA | -64.15M | -184.74M | -63.93M | -31.47M | -17.65M | -8.22M |
| EBITDA Ratio | -58.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -89.88M | -191.26M | -65.02M | -32.10M | -17.97M | -8.31M |
| Operating Income Ratio | -81.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.85M | 2.58M | 49.00K | 1.00K | 2.00K | 999.00 |
| Income Before Tax | -70.03M | -188.68M | -64.97M | -32.10M | -17.97M | -8.31M |
| Income Before Tax Ratio | -63.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 663.00K | -2.58M | -1.04M | 422.70K | 154.14K | 0.00 |
| Net Income | -70.69M | -186.10M | -63.93M | -32.10M | -17.97M | -8.31M |
| Net Income Ratio | -64.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.47 | -4.22 | -1.79 | -0.96 | -0.52 | -50.17 |
| EPS Diluted | -1.47 | -4.22 | -1.79 | -0.96 | -0.52 | -50.17 |
| Weighted Avg Shares Out | 48.06M | 44.11M | 35.74M | 33.54M | 34.78M | 165.58K |
| Weighted Avg Shares Out (Dil) | 48.06M | 44.11M | 35.74M | 33.54M | 34.78M | 165.58K |
ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights
Is a Surprise Coming for Arcellx (ACLX) This Earnings Season?
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition
Arcellx to Participate in Two Upcoming Investor Conferences
7 Biotech Stocks to Get In Now Before Investors Catch On
Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year?
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
Source: https://incomestatements.info
Category: Stock Reports